For the quarter ending 2026-03-31, CTSO made $8,864K in revenue. -$5,129K in net income. Net profit margin of -57.86%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue, net | 8,864 | 9,233.762 | 9,485 | 9,617 |
| Cost of goods sold | 2,734 | 2,430.359 | 2,819 | 2,803 |
| Gross profit | 6,130 | 6,803.403 | 6,666 | 6,814 |
| Research and development, net of grant income | 1,025 | 1,625* | 918 | 1,262 |
| Selling, general and administrative | 8,149 | 9,436.12 | 8,610 | 9,167 |
| Restructuring | - | 128* | - | - |
| Total operating expenses | 9,174 | 11,188.195 | 9,528 | 10,429 |
| Loss from operations | -3,044 | -4,384.792 | -2,862 | -3,615 |
| Interest expense, net | -857 | -745.866 | -645 | -616 |
| Gain (loss) on foreign currency transactions | -1,228 | 193.016 | -64 | 6,178 |
| Loss on abandoned patents | - | 559 | - | - |
| Total other income (expense), net | -2,085 | -1,111.85 | -709 | 5,562 |
| Loss before benefit from income taxes | - | -4,695* | -3,571 | - |
| Benefit from income taxes | - | 802* | -401 | - |
| Net loss | -5,129 | -5,496.642 | -3,170 | 1,947 |
| Basic EPS | -0.08 | -0.087 | -0.05 | 0.03 |
| Diluted EPS | -0.08 | -0.094 | -0.05 | 0.03 |
| Basic Average Shares | 62,738,827 | 62,832,598 | 62,753,959 | 62,608,598 |
| Diluted Average Shares | 62,738,827 | 58,274,819 | 62,753,959 | 67,166,377 |
Cytosorbents Corp (CTSO)
Cytosorbents Corp (CTSO)